In patients with persistent, moderate-to-severe asthma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as compared with placebo, was associated with ...

Asthma exacerbation rates ranged from 0.91 to 1.37 for the placebo group and from 0.32 to 0.58 for the dupilumab group. Exacerbations peaked in winter with placebo and in autumn with dupilumab.

Please provide your email address to receive an email when new articles are posted on . Dupilumab significantly improved asthma control and quality of life among children aged 6 to 11 years with ...

The annualized rate of severe asthma exacerbations was 0.46 (95% confidence interval [CI], 0.39 to 0.53) among patients assigned to 200 mg of dupilumab every 2 weeks and 0.87 (95% CI, 0.72 to 1.05 ...

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma ...

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. New England Journal of Medicine , 2021; 385 (24): 2230 DOI: 10.1056/NEJMoa2106567 Cite This Page : ...

A total of 6642 patients with asthma (n = 2876), CRSwNP (n = 574), AD (n = 3145), and EoE (n = 47) were assessed for the effect of dupilumab on blood eosinophil counts over time, rates of ...

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lu ...

or Dupilumab, a treatment for children between ages 6 and 11 with moderate to severe uncontrolled asthma. Findings revealed significantly reduced asthma attacks. Of the 408 children in the study ...

Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high daily OCS doses at ...

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

Results from the VOYAGE study of dupilumab (Dupixent) showed that the monoclonal antibody significantly reduced exacerbations in children ages 6-11 with uncontrolled moderate-to-severe asthma ...